A Randomized, Open-label Study to Compare Efficacy and Safety of A1001 and Enzyme Replacement Therapy (ERT) in Patients with Fabry Disease and AS1001-Responsive GLA Mutations, Who Were Previously Treated with ERT
|Effective start/end date||3/1/13 → 6/1/13|
- Amicus Therapeutics
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.